Sequent Scientific (VIYASH) Share Price falls 5.18% to Rs 263.8; what moved the stock today
- August 26, 2026
- Posted by: Harsh Piplani
- Category: News
Sequent Scientific fell to Rs 263.8, down 5.18% today, with a market capitalisation of Rs 11,998.48 crore. The move keeps the stock in focus for readers tracking price action, valuation and sector context.
Sequent Scientific Share Price declined from Rs 278.2 at the previous close to Rs 263.8 in the latest session. The day change was Rs -14.4, equal to -5.18%, and the company’s market capitalisation stood at Rs 11,998.48 crore. The supplied data confirms the move, but it does not identify a company-specific catalyst, so the decline should be read as a verified market event rather than a named-news reaction.
The session opened at Rs 271, touched an intraday high of Rs 271.35 and a low of Rs 262.4, and finished close to the day’s bottom. Turnover was Rs 197.93 crore. Sequent Scientific is tagged as a Mid Cap in the supplied data, which gives size context but does not explain the fall. For investors reading the stock news update, the key point is that the price action is real and measurable, while the trigger remains unspecified in the provided information.
That makes the latest move a matter of stock analysis, not speculation. The available numbers allow a grounded look at the session, the valuation profile and the broader healthcare benchmark. Readers searching for Sequent Scientific Latest News or Sequent Scientific Share News can rely on the verified figures below.
Sequent Scientific (VIYASH) Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 263.8 |
| Previous Close | Rs 278.2 |
| Today's Move | -Rs 14.40 (-5.18%) |
| Open | Rs 271 |
| High | Rs 271.35 |
| Low | Rs 262.4 |
| Turnover | Rs 197.93 crore |
| Market Capitalisation | Rs 11,998.48 crore |
| Market Cap Category | Mid Cap |
The stock opened below the previous close and stayed under that level for the full session. Its high of Rs 271.35 was only slightly above the open, while the low of Rs 262.4 sat very close to the closing price. That tight finish near the low shows a session that ended under pressure, even though the trading range itself was not wide.
On a simple price basis, Sequent Scientific Share Price lost Rs 14.4 in one day. The combination of a lower close, a modest intraday band and turnover of Rs 197.93 crore makes the session notable for market-watchers scanning top decliners. The supplied data confirms the move, but not a direct catalyst.
Market-cap context also matters. At Rs 11,998.48 crore, the company sits above the sector median market cap in the benchmark set, while remaining below the sector average. That places the stock in a larger part of the healthcare universe, even though the day’s decline is the immediate headline.
Sequent Scientific (VIYASH) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 11,998.48 crore |
| P/E Ratio | 71.5x |
| P/B Ratio | 4.35x |
| ROE | 9.06% |
| ROCE | 13.1% |
| EPS | Rs 3.89 |
| Book Value Per Share | Rs 63.92 |
| Dividend Yield | 0% |
Sequent Scientific Fundamental Analysis starts with valuation. The stock trades at a P/E of 71.5 and a P/B of 4.35. ROE is 9.06%, ROCE is 13.1%, EPS is Rs 3.89 and book value is Rs 63.92 per share. Dividend yield is 0. These figures matter because they show a company priced at a meaningful earnings multiple even though profitability ratios are moderate.
For Sequent Scientific Share Price, the valuation picture is important precisely because the supplied dataset does not include revenue, net profit, margin, debt or cash-flow data. The analysis therefore stays anchored to the verified metrics only. That is a more reliable reading than trying to infer a reason for the daily fall from information that was not provided.
In practical terms, the stock appears expensive on earnings versus the broader benchmark, while return ratios sit below some sector norms. That does not create a forecast or recommendation, but it does give context for Sequent Scientific Stock Analysis and for anyone comparing the move with the company’s fundamentals.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 71.5x |
| Benchmark Median P/E | 30.52x |
| Benchmark Average P/E | 46.79x |
| Benchmark P/E Range | 2.94x to 717.81x |
| Company P/B Ratio | 4.35x |
| Benchmark Median P/B | 2.71x |
| Benchmark Average P/B | 4.22x |
| Company ROE | 9.06% |
| Benchmark Median ROE | 11.82% |
| Benchmark Average ROE | 11.28% |
| Company ROCE | 13.1% |
| Benchmark Median ROCE | 13.88% |
| Benchmark Average ROCE | 13.78% |
| Company Market Capitalisation | Rs 11,998.48 crore |
| Benchmark Median Market Cap | Rs 613.53 crore |
| Benchmark Average Market Cap | Rs 13,734.53 crore |
Sequent Scientific operates in Healthcare and the Pharmaceuticals & Drugs industry. The benchmark set covers 201 companies, giving a useful frame for Sequent Scientific Share Price and valuation comparison. The company’s P/E of 71.5 is above the sector median of 30.52 and average of 46.79. Its P/B of 4.35 is also above the median of 2.71 and slightly above the average of 4.22.
Profitability sits a little softer than the benchmark. ROE of 9.06% is below the sector median of 11.82% and the average of 11.28%. ROCE of 13.1% is slightly below the median of 13.88% and the average of 13.78%. Market capitalisation of Rs 11,998.48 crore is far above the sector median of Rs 613.53 crore, while remaining below the sector average of Rs 13,734.53 crore.
The wider industry also shows a broad valuation spread, with P/E ranging from 2.94 to 717.81 and P/B ranging from -11.91 to 27.56. Against that backdrop, the stock sits in a premium valuation zone, which helps explain why readers track Sequent Scientific Share Price alongside sector data rather than in isolation.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | SUNPHARMA | 4,58,248.99 | 38.03 | 5.32 | 14.85 | 19.11 |
| Divi's Laboratories | DIVISLAB | 2,25,648.29 | 78.78 | 13.05 | 16.19 | 21.51 |
| Torrent Pharmaceuticals | TORNTPHARM | 1,84,891.11 | 85.81 | 20.85 | 26.76 | 19.27 |
| Cipla | CIPLA | 1,15,926.93 | 34.03 | 3.26 | 11.83 | 16 |
| Zydus Lifesciences | ZYDUSLIFE | 1,09,825.17 | 24.98 | 4.18 | 19.69 | 21.39 |
Peer comparison shows Sequent Scientific at a higher earnings multiple than Cipla, Zydus Lifesciences, Dr. Reddy’s Laboratories and Sun Pharma, while still below Divi’s Laboratories and Torrent Pharmaceuticals. Its P/B of 4.35 is above Cipla and Dr. Reddy’s, close to Zydus Lifesciences, and below Sun Pharma, Divi’s and Torrent.
ROE at 9.06% is below every peer listed in this comparison set. ROCE at 13.1% is also below Sun Pharma, Divi’s, Torrent, Cipla and Zydus Lifesciences, and slightly below Dr. Reddy’s at 13.75%. For Sequent Scientific Stock Analysis, those ratios provide the clearest relative context.
In market-cap terms, Sequent Scientific’s Rs 11,998.48 crore is larger than several peers in the broader set, including Cipla, Zydus Lifesciences, Lupin, Dr. Reddy’s, Mankind Pharma and Aurobindo Pharma, but far below Sun Pharma, Divi’s and Torrent.
Why Investors Are Watching Sequent Scientific
- Sequent Scientific Share Price fell 5.18% today, closing at Rs 263.8 versus Rs 278.2 previously.
- The session opened at Rs 271, reached Rs 271.35 and touched Rs 262.4 before ending near the low.
- Market capitalisation stood at Rs 11,998.48 crore, and the stock is classified as a Mid Cap.
- P/E is 71.5, P/B is 4.35, ROE is 9.06% and ROCE is 13.1%.
- In the same industry, the P/E sits above the median of 30.52 and average of 46.79, while ROE stays below the median of 11.82.
About Sequent Scientific
Sequent Scientific is classified in the Healthcare sector and the Pharmaceuticals & Drugs industry. The supplied benchmark set uses the same industry for valuation comparison. That is the main business context available in this update.
The article therefore focuses on the verified market data: the share price movement, the valuation ratios, the profitability metrics and the sector benchmark. That is the most reliable way to read Sequent Scientific Share Price and stock performance from the information supplied today.
Track Sequent Scientific Share Price on Univest
Use Sequent Scientific (VIYASH) live share-price page,Univest top decliners screener,Univest market blogsto review live stock data, top decliners and related market analysis.
Track Sequent Scientific Share Price on Univest for live updates, share price news, fundamental ratios, market cap context and sector comparisons. Univest also helps users review 52-week levels, company overview data and market insights in one place.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Why did Sequent Scientific Share Price fall today?
Ans. The supplied data confirms that Sequent Scientific Share Price fell 5.18% to Rs 263.8 from Rs 278.2. It does not establish a company-specific catalyst, so the move should be read as a verified price event.
What is Sequent Scientific Share Price Today?
Ans. Sequent Scientific Share Price Today is Rs 263.8. The stock declined by Rs 14.4 on the day, and the market capitalisation stood at Rs 11,998.48 crore in the latest update.
What do the valuation metrics show for Sequent Scientific?
Ans. Sequent Scientific trades at a P/E of 71.5 and a P/B of 4.35. EPS is Rs 3.89, book value is Rs 63.92 and dividend yield is 0, which gives valuation context.
How does Sequent Scientific compare with sector benchmarks?
Ans. In the same-industry benchmark, Sequent Scientific’s P/E of 71.5 is above the median 30.52 and average 46.79. Its ROE of 9.06 is below the median 11.82, while ROCE of 13.1 is slightly below the median 13.88.
How does Sequent Scientific compare with peers?
Ans. Compared with peers such as Sun Pharma, Cipla, Zydus Lifesciences and Lupin, Sequent Scientific has a higher P/E than several names and a lower ROE than all listed peers. That is useful for stock analysis.
Should investors track Sequent Scientific Share Price on Univest?
Ans. Yes. Univest lets users track Sequent Scientific Share Price alongside market cap, valuation ratios, sector context and stock updates. That makes it easier to follow the latest news and broader performance.
